发明授权
- 专利标题： Anti-NKG2A antibodies and uses thereof
- 专利标题（中）： 抗NKG2A抗体及其用途
-
申请号： US13477888申请日： 2012-05-22
-
公开(公告)号： US08901283B2公开(公告)日： 2014-12-02
- 发明人: Petrus Johannes Louis Spee , Soeren Berg Padkaer
- 申请人： Petrus Johannes Louis Spee , Soeren Berg Padkaer
- 申请人地址： DK Bagsvaerd
- 专利权人： Novo Nordisk A/S
- 当前专利权人： Novo Nordisk A/S
- 当前专利权人地址： DK Bagsvaerd
- 代理机构： Saliwanchik, Llyod & Eisenschenk
- 优先权： EP06116429 20060630
- 主分类号： C07K16/28
- IPC分类号： C07K16/28 ; A61K39/00
摘要：
Described herein are anti-NKG2A antibodies suitable for human therapy, including humanized versions of murine anti-NKG2A antibody Z270, as well as related methods and materials for producing and using such antibodies. Exemplary complementarity-determining regions (CDRs) sequences and sites for optional amino acid back-substitutions in framework region (FR) and/or CDRs of such antibodies are also described.
公开/授权文献
- US20120237510A1 Anti-NKG2A Antibodies and Uses Thereof 公开/授权日：2012-09-20
信息查询
